Core Points - The announcement details a change in the equity stake of a major shareholder, 共青城坤舜, in 奥瑞德光电股份有限公司, reducing its holding from 5.99% to 5.00% [1][2] - 共青城坤舜 sold 27,424,300 shares between May 29, 2025, and July 9, 2025, representing 0.99% of the company's total shares [1][2] - The reduction in shares does not trigger a mandatory takeover bid and will not change the company's controlling shareholder [2] Summary of Equity Change - Before the change, 共青城坤舜 held 165,600,000 shares, which was 5.99% of the total share capital [1] - After the change, 共青城坤舜 holds 138,175,700 shares, which is 5.00% of the total share capital [1][2] - The equity change was part of a previously disclosed share reduction plan [2] Subsequent Actions - The company will prepare a simplified equity change report in accordance with relevant regulations and disclose it on the Shanghai Stock Exchange website [1] - The reduction plan has not been fully implemented as of the announcement date [3]

奥瑞德光电股份有限公司 简式权益变动报告书 上市公司名称： 奥瑞德光电股份有限公司 股票上市地点：上海证券交易所 股票简称： 奥瑞德 股票代码：600666 信息披露义务人：共青城坤舜创业投资合伙企业（有限合伙） 住所：江西省九江市共青城市基金小镇内 通讯地址：江西省九江市共青城市基金小镇内 股份变动性质：股份减持，持股比例触及5%刻度 签署日期： 2025 年7月9日 1 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称为"《证券 法》"）、《上市公司收购管理办法》（以下简称："《收购办法》"）、《公开 发行证券的公司信息披露内容提要与格式准则第 15 号——权益变动报告书》（以下 简称"《准则 15 号》"）及其他相关的法律、法规编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违反 信息披露义务人公司章程或内部规则中的任何条款，或与之相冲突。 三、依据《证券法》《收购办法》《准则 15 号》的规定，本报告书已全面披 露信息披露义务人在奥瑞德光电股份有限公司中拥有权益的股份变动情况。 截至本报告书签署日，除本报告书披露的信息外，信息披露义务人没有通 ...

证券代码：600666 证券简称：奥瑞德 公告编号：临2025-030 奥瑞德光电股份有限公司 关于持股 5%以上股东权益变动至 5%的提示性公告 1 / 2 本次权益变动属于持股 5%以上股东履行此前披露的股份减持计划，不触及要 约收购。 本次权益变动后，共青城坤舜创业投资合伙企业（有限合伙）（以下简称"共 青城坤舜"）持有奥瑞德光电股份有限公司（以下简称"公司"）的股份数量 为 138,175,700 股，占公司总股本的比例为 5.00%。 本次权益变动不会导致公司控股股东发生变化。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司于 2025 年 7 月 10 日收到公司股东共青城坤舜出具的《简式权益变动报告书》， 共青城坤舜于 2025 年 5 月 29 日-2025 年 7 月 9 日通过大宗交易与集中竞价方式减持公 司股份 27,424,300 股（占公司总股本的 0.99%）。本次权益变动前，共青城坤舜持有 公司股份 165,600,000 股，占公司总股本的 5.99%。本次权益变动后，共青 ...

China Audit Asia Pacific Certified Public Accountants LLP 中审亚太会计师事务所(特殊普通合伙) 关于奥瑞德光电股份有限公司 2024 年年度报告的信 息披露监管工作函回复 上海证券交易所上市公司管理二部: 根据我们收到奥瑞德光电股份有限公司(以下简称"公司"或"奥瑞德公 司")转来的贵部 2025 年 5 月 29 日下发的《关于奥瑞德光电股份有限公司 2024 年年度报告的信息披露监管工作函》(上证公函【2025】0682 号)(以下简称"工 作函"),针对工作函中要求会计师发表意见的事项,我们进行了逐项的核查、 落实与说明。 建立健全财务会计管理体系,并保证账簿记录的真实、完整是奥瑞德公司的 责任。我们的责任是依据《中国注册会计师执业准则》的规定,并根据工作函中 需要我们发表意见的事项出具真实、准确的专项说明。现将核查情况及核查结果 说明如下: 一、关于蓝宝石业务 1. 关于蓝宝石业务开展情况。年报显示,本年度公司蓝宝石制品实现营收 2.16亿元,同比微降1.60%,发生成本2.03亿元,蓝宝石制品毛利率上升至6.14%, 同比转正。分产品来看,蓝 ...

证券代码：600666 证券简称：奥瑞德 公告编号：临2025-029 奥瑞德光电股份有限公司 关于上海证券交易所对公司2024年年度报告的信息披露监 管工作函的回复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 奥瑞德光电股份有限公司（以下简称"公司"或"奥瑞德股份"）于近期收到上海证券 交易所下发的《关于奥瑞德光电股份有限公司2024年年度报告的信息披露监管工作函》 （上证公函【2025】0682号）（以下简称"工作函"），现将工作函相关问题回复如下： 一、关于蓝宝石业务 1、关于蓝宝石业务开展情况。年报显示，本年度公司蓝宝石制品实现营收 2.16亿元， 同比微降 1.60%，发生成本 2.03 亿元，蓝宝石制品毛利率上升至 6.14%，同比转正。分 产品来看，蓝宝石晶棒实现营收 3,400.59万元，同比增长 33.22%，蓝宝石晶片实现营收 15,869.18万元，同比下滑 6.21%。请公司：(1)补充披露本年度蓝宝石制造业务前五大客户、 关联关系、所属地区、收入确认金额、产品类型、是否属于本年新增客户或供应商 ...

New Stock Offerings - Jichuan Pharmaceutical (600566) has a tender offer period from June 18, 2025, to July 17, 2025[1] - *ST Yazhen (603389) has a tender offer period from June 10, 2025, to July 9, 2025[1] - Zhongcheng Tui (300208) has 11 trading days remaining until the last trading day[1] Delisting and Trading Reminders - Tui Shi Jin Gang (600190) has 11 trading days remaining until the last trading day[1] - Hengli Tui (000622) is in the delisting arrangement period with 8 trading days remaining[1] - Tui Shi Jiu You (600462) has 7 trading days remaining until the last trading day[1] Market Volatility - Beifang Changlong (301357) reported severe abnormal fluctuations[1] - Multiple companies, including Jichuan Pharmaceutical and *ST Yazhen, are under scrutiny for trading anomalies[1]

Core Viewpoint - The stock of Aorede (600666) experienced a significant decline of 8.61% on the trading day, with a turnover rate of 21.51% and a total transaction value of 1.774 billion yuan, indicating high volatility and trading activity [2]. Trading Activity - The stock was listed on the Shanghai Stock Exchange due to a daily price deviation of -9.00%, with a net buying amount from brokerage seats totaling 78.6188 million yuan [2]. - The top five brokerage seats accounted for a total transaction value of 350 million yuan, with a buying transaction value of 214 million yuan and a selling transaction value of 135 million yuan, resulting in a net buying of 78.6188 million yuan [2]. - The largest buying brokerage was Goldman Sachs (China) Securities, which purchased 57.9284 million yuan, while the largest selling brokerage was East Asia Qianhai Securities, which sold 48.8010 million yuan [2]. Fund Flow - The stock saw a net outflow of 145 million yuan in main funds, with a significant outflow of 133 million yuan from large orders and 12.2697 million yuan from medium orders. Over the past five days, the net outflow of main funds reached 38.6727 million yuan [2]. Financial Performance - Aorede's Q1 financial report revealed that the company achieved an operating income of 98.3838 million yuan, representing a year-on-year growth of 12.74%. However, the net profit was reported at -8.3320 million yuan [2].

New Stock Issuance - The new stock "同宇新材" (code: 301630) is listed at an issuance price of 84.00[1] - "信通电子" (code: 001388) has an issuance price of 16.42[1] Rights Issues and Announcements - "济川药业" (code: 600566) has a tender offer period from June 18, 2025, to July 17, 2025[1] - "中程退" (code: 300208) has 13 trading days remaining until the last trading day[1] - "退市锦港" (code: 600190) also has 13 trading days remaining until the last trading day[1] - "恒立退" (code: 000622) has 10 trading days remaining until the last trading day[1] Abnormal Fluctuations - "浙江东日" (code: 600113) reported severe abnormal fluctuations[1] - "汇金股份" (code: 300368) is noted for abnormal fluctuations[3]

Core Viewpoint - The company has experienced abnormal stock trading fluctuations, with a cumulative closing price increase of 20% over three consecutive trading days, prompting the need for disclosure and clarification regarding its operational status and any undisclosed significant information [1][4]. Group 1: Company Operational Status - The company and its subsidiaries are operating normally, with no significant changes in the market environment or industry policies [2]. - The company has confirmed with its controlling shareholder, Qingdao Zhican, that there are no undisclosed significant matters, including major asset restructuring or significant transactions [2][3]. - No media reports or market rumors have been identified that could impact the company's stock trading price [2]. Group 2: Risks and Uncertainties - The company is investing in a computing power service business, which involves substantial capital investment and is subject to various uncertainties, including macroeconomic conditions and industry competition [3]. - There is uncertainty regarding the performance of compensation obligations due to the judicial freeze on shares held by key individuals, which may affect the company's ability to recover compensation [3][4]. - Financial investors have significantly reduced their holdings, with a total of 962,311,324 shares sold, representing 81.80% of their previously acquired shares, which may continue to impact stock performance [4]. Group 3: Stock Trading Fluctuations - The company's stock experienced a significant price deviation, with a cumulative increase of 20% over three trading days, indicating substantial volatility in the secondary market [1][4]. - Investors are advised to exercise caution and make rational investment decisions in light of the observed trading risks [4]. Group 4: Board Statement - The company's board confirms that there are no undisclosed matters that should have been reported according to the relevant stock exchange rules, and all previously disclosed information remains accurate [4].

Core Viewpoint - Multiple listed companies in the Shanghai and Shenzhen stock markets have announced significant updates, including changes in financing, business performance, and strategic decisions, which may impact investor sentiment and market dynamics [1]. Financing and Restructuring - Guanhao Biological has withdrawn its application for refinancing, leading to the termination of the review process by the Shenzhen Stock Exchange [3]. - Jinhongshun has terminated its major asset restructuring plan due to a lack of consensus among parties involved [6]. - Yuyuan Co. plans to issue bonds not exceeding 40 billion yuan to adjust its debt structure and replenish working capital [23]. Business Performance and Uncertainties - Aored has highlighted significant uncertainties in its computing power leasing services due to heavy asset investment and potential market fluctuations [4]. - Guoyao Modern intends to publicly transfer 51% of its subsidiary Guoyao Hason's shares, as the subsidiary has been underperforming with continuous losses since 2021 [5]. - Chengbang Co. reported that its subsidiary, Xinchun Electronics, has a small business scale and faces intense competition in the semiconductor storage industry, with projected revenues of 111 million yuan and a net profit of 933,800 yuan for 2024 [9]. Stock Market Activity - Alloy Investment announced a change in its controlling shareholder to Jiuzhou Hengchang, with stock trading resuming on July 1 [7]. - Changcheng Military Industry reported significant stock price volatility, with a cumulative increase of over 100% in the last 10 trading days, indicating potential irrational market behavior [8]. Earnings Forecasts - Hanyu Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, recovering from a loss in the previous year, driven by international business growth [12]. - Taotao Vehicle anticipates a net profit increase of 70.34% to 97.81% for the same period, reflecting strong sales performance [13]. - Weichai Heavy Machinery projects a net profit increase of 40% to 60%, benefiting from industry policy support and demand growth [15]. Major Contracts and Projects - China Railway has won contracts for overseas construction projects totaling approximately 5.343 billion yuan [17]. - Zhonggong International has signed a 175 million yuan engineering consulting service contract [18]. - Hezhan Energy has entered into a 177 million yuan contract for the sale of steel-concrete towers [19].